Abilify: Advanced Antipsychotic for Symptom Control and Stability
Abilify
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.90 | $54.00 (0%) | 🛒 Add to cart |
| 90 | $0.78 | $81.00 $70.00 (14%) | 🛒 Add to cart |
| 180 | $0.66 | $162.00 $118.00 (27%) | 🛒 Add to cart |
| 270 | $0.61 | $243.00 $166.00 (32%) | 🛒 Add to cart |
| 360 | $0.59
Best per pill | $324.00 $214.00 (34%) | 🛒 Add to cart |
| Product dosage: 15mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.53 | $46.00 (0%) | 🛒 Add to cart |
| 60 | $1.08 | $92.00 $65.00 (29%) | 🛒 Add to cart |
| 90 | $0.93 | $138.00 $84.00 (39%) | 🛒 Add to cart |
| 120 | $0.85 | $184.00 $102.00 (45%) | 🛒 Add to cart |
| 180 | $0.78 | $276.00 $141.00 (49%) | 🛒 Add to cart |
| 270 | $0.73 | $414.00 $198.00 (52%) | 🛒 Add to cart |
| 360 | $0.70
Best per pill | $552.00 $253.00 (54%) | 🛒 Add to cart |
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.47 | $74.00 (0%) | 🛒 Add to cart |
| 60 | $1.75 | $148.00 $105.00 (29%) | 🛒 Add to cart |
| 90 | $1.51 | $222.00 $136.00 (39%) | 🛒 Add to cart |
| 120 | $1.38 | $296.00 $166.00 (44%) | 🛒 Add to cart |
| 180 | $1.27 | $444.00 $228.00 (49%) | 🛒 Add to cart |
| 270 | $1.19 | $666.00 $321.00 (52%) | 🛒 Add to cart |
| 360 | $1.15
Best per pill | $888.00 $413.00 (53%) | 🛒 Add to cart |
Synonyms | |||
Abilify (aripiprazole) is an atypical antipsychotic medication engineered to provide a sophisticated mechanism of action for managing complex psychiatric conditions. It functions as a partial agonist, offering a unique modulatory effect on dopamine and serotonin receptors, which contributes to its efficacy and generally favorable tolerability profile. This medication is a cornerstone in the long-term management of schizophrenia, bipolar disorder, and as an adjunct in major depressive disorder, providing patients with a path toward sustained symptom control and improved functional outcomes. Its distinct pharmacological profile allows for a nuanced approach to neurochemical stabilization, making it a valuable tool in a comprehensive psychiatric treatment plan.
Features
- Active Pharmaceutical Ingredient: Aripiprazole.
- Pharmacological Class: Atypical antipsychotic; dopamine D2 and serotonin 5-HT1A partial agonist, serotonin 5-HT2A antagonist.
- Available Formulations: Oral tablets, orally disintegrating tablets, oral solution, and extended-release intramuscular injectable suspension (Abilify Maintena).
- Dosing Flexibility: Available in multiple strengths (e.g., 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg tablets) to allow for precise dose titration.
- Receptor Profile: Exhibits high affinity for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors, and moderate affinity for other serotonin, alpha-adrenergic, and histamine H1 receptors.
Benefits
- Achieves and maintains symptom control in schizophrenia, reducing the frequency and intensity of psychotic episodes.
- Provides effective stabilization of acute manic and mixed episodes associated with bipolar I disorder and supports long-term maintenance.
- Enhances the antidepressant effect when used as an adjunctive treatment for Major Depressive Disorder (MDD).
- Offers a generally lower propensity for certain side effects, such as significant weight gain and metabolic disturbances, compared to some other antipsychotics.
- The availability of a long-acting injectable (LAI) formulation improves adherence and provides consistent drug delivery, reducing the risk of relapse.
- The partial agonist activity may contribute to a reduced risk of secondary negative symptoms and extrapyramidal side effects (EPS) compared to full antagonists.
Common use
Abilify is FDA-approved for the treatment of multiple psychiatric conditions. Its primary use is for the treatment of schizophrenia in adults and adolescents aged 13 years and older. It is also indicated for the acute and maintenance treatment of manic and mixed episodes associated with Bipolar I Disorder as both monotherapy and as an adjunct to lithium or valproate in adults and pediatric patients aged 10 years and older. Furthermore, it is used as an adjunctive therapy to antidepressants for the treatment of Major Depressive Disorder (MDD) in adults. Off-label, it may be used under specialist supervision for conditions such as irritability associated with autistic disorder (in pediatric patients), Tourette’s disorder, and treatment-resistant anxiety disorders.
Dosage and direction
Dosage is highly individualized based on the condition being treated, patient response, and tolerability. Treatment must be initiated and supervised by a healthcare professional.
- Schizophrenia (Adults): The recommended starting and target dose is 10 or 15 mg administered once daily. Dosage should not be increased before 2 weeks, the time needed to achieve steady state.
- Schizophrenia (Adolescents 13-17 years): Starting dose is 2 mg/day, titrated to 5 mg/day after 2 days, and then to the target dose of 10 mg/day. Subsequent increases should be in 5 mg increments.
- Bipolar Mania (Adults): Monotherapy starting dose is 15 mg once daily. The dose may be increased to 30 mg once daily based on clinical response.
- Adjunctive Treatment of MDD (Adults): The recommended starting dose is 2-5 mg/day. The dose should be titrated at increments of up to 5 mg at intervals of no less than one week. The maximum recommended dose is 15 mg/day.
- Administration: Tablets can be taken with or without food. The oral solution must be used with the provided calibrated dispenser. The orally disintegrating tablet should be placed on the tongue without liquid.
Precautions
- Elderly Patients with Dementia-Related Psychosis: There is an increased risk of death and cerebrovascular adverse events. Abilify is not approved for this use.
- Suicidal Thoughts and Behaviors: Antidepressants may increase the risk of suicidal thinking and behavior in children, adolescents, and young adults. Patients of all ages started on therapy should be monitored appropriately.
- Metabolic Changes: Monitor for potential hyperglycemia/diabetes mellitus, dyslipidemia, and weight gain.
- Orthostatic Hypotension: May cause dizziness, lightheadedness, and tachycardia due to its alpha-adrenergic antagonism, especially during initial dose titration.
- Leukopenia, Neutropenia, and Agranulocytosis: Has been reported with antipsychotics. Patients with a pre-existing low white blood cell count (WBC) or a history of drug-induced leukopenia/neutropenia should be monitored.
- Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use; use with caution in patients at risk for aspiration pneumonia.
- Cognitive and Motor Impairment: May impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles.
Contraindications
Abilify is contraindicated in patients with a known hypersensitivity to aripiprazole or any component of the formulation. Hypersensitivity reactions ranging from pruritus/urticaria to anaphylaxis have been reported.
Possible side effect
Like all medications, Abilify can cause side effects, which are often dose-dependent. Not all patients will experience them.
- Very Common (≥1/10): Akathisia (feeling of inner restlessness and need to move), headache, insomnia.
- Common (≥1/100 to <1/10): Sedation/somnolence, fatigue, blurred vision, constipation, nausea, vomiting, dyspepsia, dizziness, lightheadedness, anxiety, restlessness, tremor, salivary hypersecretion.
- Uncommon (≥1/1,000 to <1/100): Orthostatic hypotension, syncope, tachycardia, weight gain, rash, muscle rigidity.
- Rare but Serious: Neuroleptic malignant syndrome (NMS), tardive dyskinesia, seizures, hyperglycemia, diabetic ketoacidosis, hyperosmolar coma, leukopenia, neutropenia.
Drug interaction
Aripiprazole is primarily metabolized by CYP3A4 and CYP2D6 enzymes. Concomitant use with inhibitors or inducers of these enzymes will affect its plasma concentration.
- Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole): Double the Abilify dose.
- Strong CYP2D6 Inhibitors (e.g., quinidine, fluoxetine, paroxetine): Half the Abilify dose.
- Strong CYP3A4 Inducers (e.g., carbamazepine, rifampin): Double the Abilify dose.
- Centrally Acting Drugs: Use with caution with other CNS depressants (alcohol, benzodiazepines, opioids) due to additive sedative effects.
- Antihypertensive Drugs: May enhance the hypotensive effects of certain blood pressure medications.
Missed dose
If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one.
Overdose
In case of suspected overdose, immediate medical attention is required. Supportive medical care is paramount. Symptoms of overdose may include severe sedation, coma, nausea, vomiting, tachycardia, hypotension, and seizures. Ensure a patent airway and monitor cardiac function and vital signs. There is no specific antidote for aripiprazole overdose; management involves gastric lavage (if presented early) and administration of activated charcoal.
Storage
Store Abilify tablets and oral solution at room temperature (15°-30°C or 59°-86°F). The oral solution should not be frozen. Keep the bottle of oral solution tightly closed and protect from light. Keep all medications out of the reach of children and pets.
Disclaimer
This information is for educational purposes only and is not a substitute for the professional judgment of a qualified healthcare professional in diagnosing and treating patients. The information does not cover all possible uses, directions, precautions, interactions, or adverse effects. The reader is directed to consult the full FDA-approved prescribing information and discuss any questions with their physician or pharmacist before beginning or altering any treatment regimen. Never disregard professional medical advice or delay in seeking it because of something you have read here.
Reviews
- “As a psychiatrist, Abilify’s partial agonist mechanism provides a valuable middle ground. I find it particularly useful for patients who are sensitive to the sedative or metabolic effects of other antipsychotics. The LAI formulation has been a game-changer for adherence in my practice.” – Dr. E. Vance, MD, Psychiatry.
- “The adjunctive use for MDD has allowed many of my patients with incomplete responses to SSRIs to finally achieve remission. The dosing requires careful titration to minimize akathisia, but the payoff in improved mood and function is often significant.” – Clinical Psychopharmacologist.
- “From a nursing perspective, patient education is key. We spend considerable time discussing the potential for restlessness (akathisia) so patients can report it early. The oral solution and disintegrating tablets are excellent options for patients with swallowing difficulties.” – RN, Inpatient Psychiatric Unit.
- “The evidence for its efficacy in adolescent schizophrenia and bipolar disorder is robust. It offers a critical treatment option for this vulnerable population, though vigilant monitoring for side effects is non-negotiable.” – Child and Adolescent Psychiatrist.